Accès ouvert · CC BY

Author Correction: Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma

Erratum 2022 Sciences de la santé Anglais

Résumé

The P-values for the comparisons shown in Figure 10 and reported in the text were not controlled for alpha error. We used Hochberg’s method (the modified Bonferroni method) for P-value correction; the main results remain the same after this correction, but the Article now reports adjusted P-values. The Article changed as follows. The original Figure 10 and accompanying legend appear below. Figure 10 Kaplan–Meier survival plots of ( a ), MBZ vs. DEN; ( b ), SO vs. DEN; ( c ), MBZ + SO vs. DEN; ( d ), MBZ + SO vs. SO; ( e ), MBZ + SO vs. MBZ and ( f ), survival proportions between treatment groups. Statistical analysis was done using the log rank test (Mantel-cox method). P values < 0.05 were considered significant. Full size image

Citer ce document

Younis, N. S., Ghanim, A. M. H., & Saber, S. (2022). Author Correction: Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Scientific Reports. https://doi.org/10.1038/s41598-022-17580-7

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 09/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 15

Téléchargements (hors robots) : 0

Méthode de comptage